Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | CASP3 | P42574 | 2/20 | 0.70 |
| ▸ | APAF1 | O14727 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.70 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.70 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.51 |
| ▸ | MDH2 | P40926 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580937 | 0.82 | KMT2A (1.00) | MEN1KMT2ACASP3APAF1GAA | |
| SCHEMBL31667682 | 0.82 | CASP3 (0.62) | MEN1KMT2ACASP3APAF1GAA | |
| SCHEMBL12443620 | 0.80 | PARK7 (0.47) | MEN1KMT2ACASP3APAF1GAA | |
| SCHEMBL29364860 | 0.80 | PARK7 (0.47) | MEN1KMT2ACASP3APAF1GAA | |
| SCHEMBL1431418 | 0.78 | GAA (0.51) | MEN1KMT2ACASP3APAF1GAA | |
| SCHEMBL23674994 | 0.77 | HDAC1 (0.53) | MEN1KMT2AALDH1A1PARK7MDH2 | |
| SCHEMBL30100741 | 0.77 | HDAC1 (0.53) | MEN1KMT2AALDH1A1PARK7MDH2 | |
| SCHEMBL26088987 | 0.77 | HDAC1 (0.65) | MEN1KMT2ACASP3APAF1GAA | |
| SCHEMBL4782178 | 0.76 | CHRM5 (0.68) | CASP3APAF1ALDH1A1PARK7CMA1 | |
| SCHEMBL25377649 | 0.76 | HDAC6 (0.45) | MEN1KMT2ACASP3APAF1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144881-B1 | ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| EP-2144881-A1 | ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA | AstraZeneca AB (SE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008122765-A1 | NEW COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122765-A1 | NEW COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | CYP3A7, UGT1A7, UGT2B7 | MEN1 1767/4885KMT2A 3620/4885CASP3 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.